关键词：生物治疗；血清；毒素；过敏；生物制剂；预防；治疗；疾病
摘 要：Biologic therapeutics include viruses, therapeutic serums, toxins, allergenic products, antitoxins, blood or blood components or derivatives, vaccines, and proteins (except any chemically synthesized polypeptide). These also include analogous products, arsphenamine, or derivatives of arsphenamine (or any other trivalent organic arsenic compound) for the prevention, treatment, or cure of a disease or condition. Biologics differ from small molecules in their molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics have a high molecular weight and a complex molecular structure, are usually derived from living entities, and are vulnerable to extreme temperatures (thermolabile) and light.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 06: Market segmentation by type of molecules

PART 07: Global protein therapeutics market

Introduction

Drivers, challenges, and trends

Market segmentation by type of molecules

PART 08: Global vaccines market

Introduction

Drivers, challenges, and trends

Market segmentation by end-user age group

PART 09: Global cell therapy market

Introduction

Drivers, challenges, and trends

Market size and forecast

PART 10: Geographical segmentation

Biologic therapeutics market in Americas

Biologic therapeutics market in EMEA

Biologic therapeutics market in APAC

PART 11: Market drivers

Reimbursement support for biologics

Promising drug pipeline

Focus on development of novel mechanisms

Increase in industry–academia collaborations

PART 12: Impact of drivers

PART 13: Market challenges

High cost of therapy

Stringent regulatory guidelines

Fierce market competition

Cold chain management

Poor diagnosis and screening

PART 14: Impact of drivers and challenges

PART 15: Market trends

Emergence of targeted and combination therapies

Increase in R&D

Shift in focus to untapped markets

Rise in public awareness

PART 16: Vendor landscape

Competitive scenario

Key news

Mergers and acquisitions

Market share analysis

Amgen

F. Hoffmann-La Roche

Novo Nordisk

Sanofi

Other and future prominent vendors

PART 17: Key vendor analysis

Amgen

F. Hoffmann-La Roche

Novo Nordisk

Sanofi

PART 18: Appendix

List of abbreviations

PART 19: Explore Technavio